The BioMed X Institute
The research of BioMed X team EPD - Early Intervention in Psychiatric Diseases - has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.
HEIDELBERG, GERMANY / ACCESSWIRE / May 28, 2024 / German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany. Her team has created both in vivo and in vitro platforms to study myelination of neurons and the development of oligodendrocytes - a subtype of glial cells - in the context of schizophrenia. Their novel in vitro platform for studying myelination was published last year in Cell Press - STAR Protocols (PMID: 36933222). Dr. Ercan Herbst's team has also identified a relevant mouse model exhibiting the hypomyelination pathology associated with schizophrenia to be used for future research. In addition to the cell and mouse models, the BioMed X neuroscientists have analyzed the RNA expression of different human brain regions in post-mortem samples from schizophrenia patients and controls. Their soon-to-be-published findings reveal that there are differentially expressed genes and pathways in schizophrenia brains, particularly in oligodendrocytes, when compared to control brains, which could have significant implications for designing new therapies, not only for schizophrenia but also for other neurological disorders like major depressive disorder or bipolar disorder, which share a common hypomyelination pathology.
Dr. Christian Tidona, Managing Director & Founder of the BioMed X Institute: "This is already our second successfully completed project with Boehringer Ingelheim in the field of psychiatry. We are looking forward to continuing our successful collaboration with our ongoing research projects in brain sensor development in Heidelberg and in the field of wound healing and fibrosis at our new joint XSeed Labs on the U.S. campus of Boehringer Ingelheim in Ridgefield, CT."
"Together with partners from across the global neuroscience community, we are constantly exploring new scientific avenues to address the huge unmet need of those living with mental health conditions," Hugh Marston, Global Head CNS Discovery Research at Boehringer Ingelheim, stated. "The partnership with BioMed X and the fruitful collaboration with Dr. Ercan Herbst's team has yielded exciting insights that will help us initiate projects to further progress our precision psychiatry approach to transform patients' lives."
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
SOURCE: BioMed X Institute
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Graid Technology Announces SupremeRAID SE Support for the NVIDIA GeForce RTX 5000 Series, Expanding High-Performance RAID for Workstations13.2.2025 11:00:00 CET | Press release
With Support for the NVIDIA® GeForce RTX™ 5090, 5080, 5070 Ti, 5070 and 5060, SupremeRAID™ SE Continues to Push the Boundaries of High-Performance Workstation Storage SANTA CLARA, CALIFORNIA / ACCESS Newswire / February 13, 2025 / Graid Technology, the leader in GPU-based RAID solutions, today announced that SupremeRAID™ SE now supports the entire NVIDIA® GeForce RTX™ 5000 series, delivering unparalleled RAID performance to high-end workstation users. With support for the GeForce RTX 5090, 5080, 5070 Ti, 5070, and 5060, professionals can leverage NVIDIA's most powerful GPUs to maximize NVMe SSD performance with exceptional efficiency and resilience.Graid Technology Announces SupremeRAID™ SE Support for the NVIDIA® GeForce RTX™ 5000 Series SupremeRAID™ SE is Graid Technology's bring-your-own-GPU RAID solution, designed for workstation users who demand high-speed data access, reliability, and flexibility. With support for the GeForce RTX 5000 series, users can take advantage of NVIDIA's
The Glimpse Group Reports Q2 Fiscal Year 2025 Financial Results - 50% Increase in Revenue and Positive EBITDA, Positive Cash Flow & Positive Net Income13.2.2025 08:15:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, provided financial results for its second quarter fiscal year 2025 year, ended December 31, 2024 ("Q2 FY '25"). Business Commentary by President & CEO Lyron Bentovim Financial Summary: Q2 FY '25 revenue of approximately $3.17 million, reflecting: a) 52% increase compared to Q2 FY '24 (ending December 31, 2023) revenue of approximately $2.08 million, and b) 30% increase compared to Q1 FY '25 (ending September 30, 2024) revenue of approximately $2.44 million. The increase in both comparative periods was primarily driven by an increase in Spatial Core revenues, as well as growth in our other businesses. Gross Margin for Q2 FY ‘25 was approximately 64% compared to 68% for Q2 FY ‘24. The decrease was driven
Sadot Group Inc. Announces Appointment of Ms. Catia Jorge as New Chief Executive Officer13.2.2025 08:00:00 CET | Press release
BURLESON, TEXAS / ACCESS Newswire / February 13, 2025 / Sadot Group Inc. (Nasdaq:SDOT) ("Sadot Group" or the "Company") today announced the appointment of Ms. Catia Jorge as its new Chief Executive Officer, effective immediately. Ms. Jorge, a seasoned leader in the global agri-commodity sector, joins Sadot Group at a pivotal time, as the Company transitions to focusing on expanding its platform globally. Ms. Jorge will report to the Board of Directors and lead Sadot's strategic initiatives, global operations, and business growth efforts to maximize the Company's long-term potential. A highly regarded industry veteran, Ms. Jorge brings nearly 30 years of experience in agricultural markets, commodity trading, and operational leadership. She most recently served as Brazil Country Head and Vice President/Grains Business Head Latin America for Olam Agri, where she managed a $1.0 billion annual revenue portfolio. Prior to Olam, she held leadership roles at Cargill Agricola South America expo
Cleverbridge Appoints Markus Scheuermann as Chief Financial Officer12.2.2025 05:00:00 CET | Press release
Seasoned Finance Leader Brings 20+ Years of Expertise in Financial Strategy, M&A and Digital Transformation to Cleverbridge COLOGNE, GERMANY & CHICAGO, IL / ACCESS Newswire / February 12, 2025 / Cleverbridge, a leading provider of ecommerce and billing solutions for global software and SaaS companies, today announced the appointment of Markus Scheuermann as Chief Financial Officer, effective as of April 1, 2025.Markus Scheuermann Scheuermann is a seasoned senior executive with over 20 years of experience in financial strategy, business development, M&A, and digital transformation within high-performing technology organizations. Most recently, he served as Chief Financial Officer at Thinkproject Group and has previously held key leadership roles at HolidayCheck Group, Hubert Burda Media, eBay, and McKinsey & Company. Markus will report directly to Wendi Sturgis, Cleverbridge CEO, and be part of an executive leadership team that includes CRO Kevin Feagan, CTO Radu Immenroth, and CHRO Ale
CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 202411.2.2025 11:45:00 CET | Press release
Uncertain outlook for 2025 as new immigration policies are implemented PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 11, 2025 / A new CGFNS International report indicates that a robust annual rate of nurse migration into the United States held steady in 2024 as healthcare systems continued to look to foreign-educated nurses to help address persistent staffing shortages.CGFNS International 2024 Nurse Migration Report However, in its 2024 Nurse Migration Report, the organization also said the current high rates were likely unsustainable amid persisting visa retrogression and caps on employment-based green cards for nurses, along with new immigration policies being implemented by the Trump Administration that will likely have further impact on visa availability and processing times. CGFNS, a global health workforce non-profit that verifies credentials of healthcare professionals for immigration authorities and state licensing boards, reported that in fiscal year 2024 it received
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom